Competitive Technologies to introduce Calmare pain therapy at medical conference

NewsGuard 100/100 Score

Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that it will hold a conference for the medical community on May 17, 2010, in Boston, Mass. at the Marriott Long Wharf Hotel from 9:00 a.m. to 3:30 p.m., to introduce CTT's Calmare® pain therapy to the medical community. Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, is the Italian inventor of the "Scrambler Therapy," the technology used in the Calmare medical device. Prof. Marineo will be honored by CTT at the conference and he will present the scientific basis for this revolutionary pain treatment method. Throughout the day, several physicians will present patient case studies stemming from their use of this innovative technology to treat various types of chronic pain including severe pain from cancer and chemotherapy-induced peripheral neuropathy (CIPN), failed back surgery, phantom limb syndrome, as well as pain from shingles and a variety of other maladies. Typically, the patients' pain has been resistant to other treatment methodologies, including powerful narcotic painkillers that have been linked to adverse side effects.

The physicians presenting their patient case studies will include:

  • Perry Rosenthal, MD - Founding President, Vice Chairman and Scientific Director at the Boston Foundation for Sight, and Assistant Clinical Professor of Ophthalmology, Harvard Medical School
  • Salahadin Abdi, MD - Professor and Chief, University of Miami Pain Center, Anesthesiology, Perioperative Medicine & Pain Management
  • Toby Campbell, MD - Assistant Professor of Medicine, Hematology & Oncology, University of Wisconsin, Paul J. Carbone Cancer Center
  • Stephen J. D'Amato, MD, FACEP- Medical Director, Calmar Pain Relief Therapy, Clinical Assistant Professor of Medicine, Boston University School of Medicine, and Medical Staff, Roger Williams Medical Center.

"We are pleased to be able to highlight our Calmare pain therapy medical device to physicians at this upcoming event," said John B. Nano, CTT's Chairman, President and CEO. "Having Prof. Marineo discuss his development of this technology will provide a unique perspective for physicians wanting to gain a deeper understanding of how the device functions as well as its safety and efficacy in relieving patients' pain. We are fortunate that on his first U.S visit from his research facility in Italy he is presenting to members of the medical community."

With recent media coverage focusing on the negative side effects of morphine and other powerful painkillers, the Calmare device offers physicians an effective alternative for treating high intensity oncologic and neuropathic pain, including pain resistant to opioids and other treatment methodologies. 

SOURCE Competitive Technologies, Inc.

Comments

  1. Mike Mike United States says:

    Wow! This device appears to be nothing short of miraculous for patients suffering from excruciating oncologic and neuropathic pain.

    This device should be in every major city and will likely be adopted as the standard of care.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals nerve changes linked to pain and urinary frequency in recurrent UTI sufferers